GlassScriptPhysician profile
Dina Kassab
NPI 1205273315
$4,046.34
in general payments reported to CMS, 2019-2025
30 companies · $823 in 2025
The $823 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $131 · 2021: $279 · 2022: $1,057 · 2023: $867 · 2024: $746 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.23 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $958.48 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Aspira Women'S Health INC | $663.70 | 2019-2024 | Ova1 |
| Astellas Pharma US INC | $427.46 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $240.98 | 2020-2023 | |
| Mayne Pharma Commercial LLC | $207.82 | 2022-2025 | |
| Organon LLC | $188.16 | 2022-2025 | Nexplanon, Nuvaring |
| Shield Therapeutics INC | $184.98 | 2023-2025 | Accrufer |
| Smith+Nephew, INC. | $117.00 | 2023-2025 | Pico 7 |
| Coopersurgical, INC. | $110.35 | 2022 | |
| Biogen, INC. | $101.70 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $100.51 | 2021-2022 | |
| Myriad Women'S Health, INC. | $89.16 | 2023 | Myrisk |
| Coloplast Corp | $85.03 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.15 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $66.39 | 2025 | Myfembree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $57.82 | 2020-2022 | |
| Novo Nordisk INC | $53.40 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $50.53 | 2019-2023 | Evenity, Prolia |
| Convatec INC. | $49.55 | 2023 | |
| Therapeuticsmd, INC. | $33.31 | 2019-2022 | |
| Medtronic, INC. | $31.21 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $27.51 | 2019 | |
| Agile Therapeutics, INC. | $21.00 | 2021 | |
| Gynesonics, INC. | $18.68 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Meditrina | $18.63 | 2025 | |
| Evofem Biosciences, INC. | $18.10 | 2020 | |
| Exact Sciences Corporation | $15.07 | 2025 | Cologuard Collection Kit |
| Vivus LLC | $14.42 | 2019 | |
| Exeltis, USA INC. | $12.11 | 2022 | |
| Pfizer INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Kassab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.